Just three years ago, Whakatāne’s Rachel Weatherly was thriving on a football scholarship in the United States. Today, at 23, ...

World-first Australian research suggests treating a common chronic illness during pregnancy can prevent serious birth ...

Dr. Robert Fuller leaves a legacy at UConn Health and beyond Dr. Robert Fuller (pictured in 2021) is retired from 30 years of ...

The City of Kingston has recognized six outstanding community volunteers with its Civic Awards. According to a release from ...

A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with ...

In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...

Treatment options for patients with moderately to severely active Crohn's disease have expanded in the past decade, with ...

A new study led by researchers at Mount Sinai Health System has identified distinct biological signatures in patients with mild Crohn’s disease, offering a potential pathway toward more personalized ...

Researchers at New York City-based Mount Sinai Health System have identified distinct biological markers in patients with mild Crohn’s disease, potentially paving the way for more personalized and ...

Ustekinumab is more efficacious than vedolizumab or anti-TNFs as second- or third-line biologic therapy for perianal Crohn disease.

In a major advance for patients with Crohn’s disease, a new study led by researchers at Mount Sinai Health System found that guselkumab, a medication with a mechanism of action that is new to ...